NEWARK, Calif.--(BUSINESS WIRE)--Jun. 5, 2018--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced that the Company will participate in two
upcoming investor conferences.
President and Chief Executive Officer, Dan Browne, is scheduled to
present at the William Blair 38th Annual Growth Stock
Conference in Chicago, IL on Tuesday, June 12 at 1:30pm CT.
President and Chief Executive Officer, Dan Browne, is also scheduled to
participate in a fireside chat discussion at the Goldman Sachs 39th
Annual Global Healthcare Conference in Rancho Palos Verdes, CA on
Wednesday, June 13 at 10:00am PT.
Interested parties can access the live audio webcasts for both
conferences from the Investor Relations section of the company's website
The webcast replays will be available after the conclusion of the live
presentations for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with plans to initiate
studies in upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has a
comprehensive pipeline based upon its peptide technology, including
injectable and topical formulations of daxibotulinumtoxinA. More
information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180605005089/en/
Source: Revance Therapeutics, Inc.
Revance Therapeutics, Inc.:
Ami Bavishi, 212-213-0006
Mariann Caprino, 917-242-1087
Nadine Tosk, 504-453-8344